<DOC>
	<DOC>NCT03060044</DOC>
	<brief_summary>Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus 50/500 Âµg/inhalation; a randomised, open, single centre, single dose, crossover study in healthy subjects</brief_summary>
	<brief_title>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>written informed consent obtained good general health ascertained by detailed medical history, and laboratory and physical examinations evidence of a clinically significant cardiovascular, renal, hepatic, hematological, GI, pulmonary, metabolicendocrine, neurological or psychiatric disease within the previous 2 years any condition requiring concomitant treatment (including vitamins and herbal products)or likely to need any concomitant treatment during the study. as an exception paracetamol and ibuprofen for occasional pain are allowed known hypersensitivity to the active substance(s) or the excipient (lactose, which contains small amounts of milk protein) of the drug pregnant or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>